<DOC>
	<DOC>NCT00952783</DOC>
	<brief_summary>This study is designed to follow up patients, who have achieved complete clearance of AK lesions (lesion count of 0) at Day 57 in the PEP005-020 study, over a 12 month period to assess both recurrence of Actinic Keratosis (AK) lesions and long term safety in the selected treatment area.</brief_summary>
	<brief_title>A Long Term Follow up Study of Patients Who Have Completed the PEP005-020 Study</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis, Actinic</mesh_term>
	<criteria>Inclusion Patient has provided informed consent documented by signing the Informed Consent Form (ICF) prior to any studyrelated procedures Patient achieved complete clearance of AK lesions (lesion count of 0) in the selected treatment area at the Day 57 visit in study PEP005020 Exclusion Concurrent participation in another research study which would involve the selected treatment area (except for any poststudy followup visits for previous Peplin AK study) Early termination from study PEP005020</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Peplin</keyword>
	<keyword>Actinic keratosis</keyword>
	<keyword>PEP005</keyword>
</DOC>